2,2-Dimethylthiopropionamide is used as a reagent to synthesize Dabrafenib, an inhibitor of BRAF kinase that is used to treat BRAF V600-mutation positive carcinoma. BRAF is a gene that mediates cell growth and is activated by mutations caused by cancer. 2,2-Dimethylthiopropionamide is also used as a reagent to prepare sulfonyl-substituted 4,5-diarylthiazoles, compounds that act as cyclooxygenase-2 inhibitors (anti-inflammatory agents).
To a round bottom flask (250 mL) was added trimethyl amine (5.0 g, 0.049 mol) and Lawesson's reagent (8.0g, 0.020 mol), dissolved in THF (100 mL), nitrogen, 80° C oil. The reaction bath for 4 hours. TLC monitors the reaction progress. After completion of the reaction, the solvent was removed by rotary evaporation; the residue was purified by silica gel column chromatography (petroleum ether: 1: ethyl acetate = 10) to give a white solid 2,2-Dimethylthiopropionamide (3.7 g, 65percent yield).
[1] Chemistry - A European Journal, 2013, vol. 19, # 29, p. 9655 - 9662
[2] Phosphorus and Sulfur and the Related Elements, 1986, vol. 26, p. 169 - 184
[3] Patent: CN103936728, 2016, B. Location in patent: Paragraph 0211; 0213; 0214; 0215
[4] Canadian Journal of Chemistry, 1977, vol. 55, p. 2331 - 2335
[5] Journal of the Chemical Society [Section] C: Organic, 1966, p. 686 - 691
